Goal 2: Reduce Human Disease

Rare Diseases

A study section should be seated for clinical trials on rare disease. Members of this study section should consist only of individuals who have previously performed phase I and/or phase II trials, developed IND or IDE applications, or who have extensive experience in informatic or biometric support for clinical trials. My opinion is that seating individuals on these sections who have a laboratory career in cellular or molecular science is the major impediment to the scoring of these clinical grants and new therapies. If we wait until a cellular pathway is obviously defined as pathogenic in a disease, we lose many benefits a clinical trial brings to a rare disease population.

Tags (Keywords associated with the idea)


2 net votes
2 up votes
0 down votes
Idea No. 1518